Active, not recruitingPhase 2NCT04640623
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Studying Muscular tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Janssen Research & Development, LLC
- Principal Investigator
- Janssen Research & Development, LLC Clinical TrialJanssen Research & Development, LLC
- Intervention
- TAR-200(drug)
- Enrollment
- 220 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2027
Study locations (30)
- Del Sol Research Management, LLC, Tucson, Arizona, United States
- University of Southern California, Los Angeles, California, United States
- Genesis Healthcare Partners - Genesis Research Greater Los Angeles, Sherman Oaks, California, United States
- The Urology Center of Colorado, Denver, Colorado, United States
- Foothills Urology - Golden Off, Golden, Colorado, United States
- DuPage Medical Group, Lisle, Illinois, United States
- Urology of Indiana, Greenwood, Indiana, United States
- Wichita Urology Group, Wichita, Kansas, United States
- Michigan Institute of Urology, Troy, Michigan, United States
- NYU Langone Health, New York, New York, United States
- SUNY Upstate Medical University, Syracuse, New York, United States
- Associated Medical Professionals, Syracuse, New York, United States
- Levine Cancer Institute, Charlotte, North Carolina, United States
- The Urology Group, Cincinnati, Ohio, United States
- Urologic Consultants of Southeastern Pennsylvania, Bala-Cynwyd, Pennsylvania, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04640623 on ClinicalTrials.govOther trials for Muscular tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07144319Exploration of Novel AI-enabled Blue Light Enhanced CystoscopyPhotocure
- RECRUITINGPHASE2NCT07475403Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder CancerTianjin Medical University Second Hospital
- RECRUITINGPHASE2NCT07475806A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderAstellas Pharma Global Development, Inc.
- RECRUITINGNANCT07431788The Effect of Uterine Manipulator Use During Abdominal Hysterectomy on Postoperative Sexual FunctionErkan Gol
- RECRUITINGNANCT07339761Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention StudyUniversity of Aarhus
- RECRUITINGPHASE2NCT07363057A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer SurvivorsGI Innovation, Inc.
- RECRUITINGPHASE3NCT06919965A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder CancerJanssen Research & Development, LLC
- ACTIVE NOT RECRUITINGNANCT07001670Investigation of the Effects of Tele-Yoga Training in Individuals With Lung Cancer Undergoing Lung Resection SurgeryIstanbul University